AI Article Synopsis
- - Anaemia is frequently observed after kidney transplantation, but there are no standardized management guidelines for it; most strategies are adapted from chronic kidney disease (CKD) practices.
- - Recent studies on hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHi), a new group of oral erythropoietin-stimulating agents, show encouraging results in increasing haemoglobin levels among kidney transplant patients with a safety profile similar to existing treatments like epoetin.
- - Although the initial findings regarding HIF-PHi are positive, further research is necessary to fully understand its effectiveness and safety in managing post-transplant anaemia.
Article Abstract
Purpose Of Review: Anaemia after kidney transplantation is a common finding with no uniform management guideline. Most approaches are derived from the chronic kidney disease (CKD) population. Recent advances for the treatment of anaemia in patients with CKD/End stage renal disease include hypoxia-inducible factor-prolyl hydroxylase inhibitor (HIF-PHi), a novel class of oral erythropoietin-stimulating agents (ESAs). We present relevant studies of HIF-PHi in the transplant population and its implications on the management of posttransplant anaemia.
Recent Findings: Data on HIF-PHi use in the kidney transplant population are promising. Limited data demonstrate a significant increase in haemoglobin, with a comparable safety profile to epoetin. Reported adverse effects include overcorrection and low iron stores.
Summary: Current therapeutic approaches to anaemia in the kidney transplant population is mostly derived from the CKD population. More studies are needed on HIF-Phi, a novel class of ESAs that has thus far demonstrated promise in the kidney transplant population.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/MNH.0000000000000842 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!